Novo Nordisk’s Sickle Cell Treatment Shows 27% Reduction in Vaso-Occlusive Crises, FDA Approval Expected Later in 2026
Novo Nordisk’s etavopivat reduced vaso-occlusive crises by 27% in Phase 3 trial for sickle cell disease; FDA approval expected in late 2026.
Read More